Head-To-Head Analysis: Klotho Neurosciences (NASDAQ:KLTO) & Ocugen (NASDAQ:OCGN)

Klotho Neurosciences (NASDAQ:KLTO) and Ocugen (NASDAQ:OCGN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations and risk.

Profitability

This table compares Klotho Neurosciences and Ocugen’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Klotho Neurosciences	N/A	N/A	-25.89%
Ocugen	-532.51%	-154.75%	-90.79%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Klotho Neurosciences and Ocugen, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Klotho Neurosciences	0	0	0	0	0.00
Ocugen	0	0	3	0	3.00

Ocugen has a consensus price target of $6.00, indicating a potential upside of 891.41%. Given Ocugen’s stronger consensus rating and higher possible upside, analysts plainly believe Ocugen is more favorable than Klotho Neurosciences.

Earnings & Valuation

This table compares Klotho Neurosciences and Ocugen”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Klotho Neurosciences	N/A	N/A	$1.35 million	N/A	N/A
Ocugen	$4.70 million	37.51	-$63.08 million	($0.18)	-3.36

Klotho Neurosciences has higher earnings, but lower revenue than Ocugen.

Insider & Institutional Ownership

20.1% of Klotho Neurosciences shares are owned by institutional investors. Comparatively, 10.3% of Ocugen shares are owned by institutional investors. 2.0% of Klotho Neurosciences shares are owned by company insiders. Comparatively, 4.3% of Ocugen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

About Klotho Neurosciences

Klotho Neurosciences, Inc., a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors. The company has a strategic partnership with Japan’s Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-related diseases. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. Klotho Neurosciences, Inc. is based in Omaha, Nebraska.

About Ocugen

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.